Motus GI Holdings Inc (NASDAQ:MOTS) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 928,700 shares, an increase of 18.6% from the June 30th total of 782,800 shares. Based on an average daily volume of 161,800 shares, the short-interest ratio is currently 5.7 days. Currently, 6.5% of the company’s stock are short sold.
In other Motus GI news, major shareholder Life Sciences Maste Perceptive purchased 1,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average cost of $3.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were acquired at an average cost of $3.00 per share, with a total value of $30,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 2,059,332 shares of company stock valued at $6,179,896. 18.14% of the stock is owned by corporate insiders.
Several institutional investors have recently modified their holdings of MOTS. Oracle Investment Management Inc. raised its stake in shares of Motus GI by 35.7% in the 2nd quarter. Oracle Investment Management Inc. now owns 3,766,666 shares of the company’s stock valued at $11,413,000 after purchasing an additional 991,666 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of Motus GI in the 2nd quarter valued at about $1,037,000. Granite Point Capital Management L.P. acquired a new stake in shares of Motus GI in the 2nd quarter valued at about $1,010,000. Vanguard Group Inc. acquired a new stake in shares of Motus GI in the 2nd quarter valued at about $789,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Motus GI in the 2nd quarter valued at about $446,000. Institutional investors and hedge funds own 38.34% of the company’s stock.
Motus GI (NASDAQ:MOTS) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. As a group, equities analysts predict that Motus GI will post -1.11 EPS for the current fiscal year.
A number of equities analysts have weighed in on MOTS shares. ValuEngine raised shares of Motus GI from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Piper Jaffray Companies decreased their price objective on shares of Motus GI from $8.00 to $6.00 in a research report on Friday, May 10th. Finally, Zacks Investment Research raised shares of Motus GI from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $8.25.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.